What Is Ketamine? A Complete Introduction to Ketamine Therapy

What Is Ketamine?

Ketamine is a medication that was first synthesized in 1962 by chemist Calvin Stevens at Parke-Davis Laboratories in Detroit, Michigan. Originally developed as a safer alternative to phencyclidine (PCP) for anesthesia, ketamine received approval from the U.S. Food and Drug Administration in 1970 under the brand name Ketalar. It quickly became one of the most widely used anesthetic agents in the world, valued for its remarkable safety profile and versatility.

Over the past two decades, ketamine has undergone a dramatic transformation in how the medical community views its potential. While it remains an essential anesthetic, researchers have discovered that low doses of ketamine can produce rapid and significant relief from depression, anxiety, chronic pain, and other conditions that resist conventional treatments. This discovery has positioned ketamine at the forefront of a revolution in psychiatric medicine.

Ketamine is listed on the World Health Organization's List of Essential Medicines, a designation reserved for medications considered indispensable to basic healthcare systems worldwide. In the United States, it is classified as a Schedule III controlled substance, meaning it has recognized medical applications but also carries a moderate risk for dependence when misused.

How Ketamine Works in the Brain

To understand why ketamine is generating so much excitement, it helps to know how it differs from traditional psychiatric medications at a fundamental level.

The Glutamate System

Most conventional antidepressants, such as SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors), target the brain's monoamine neurotransmitter systems, specifically serotonin, norepinephrine, and dopamine. These medications typically require consistent daily dosing over four to six weeks before patients experience meaningful symptom improvement.

Ketamine works through an entirely different pathway. It primarily targets the glutamate system, which involves the most abundant excitatory neurotransmitter in the human brain. Specifically, ketamine blocks NMDA receptors (N-methyl-D-aspartate receptors), which are a type of glutamate receptor found throughout the central nervous system.

The Neuroplasticity Cascade

When ketamine blocks NMDA receptors on certain inhibitory neurons in the brain, it triggers a complex chain of events. This blockade leads to a surge of glutamate activity that subsequently activates another type of receptor called the AMPA receptor. The downstream result is the release of brain-derived neurotrophic factor (BDNF), a protein that plays a critical role in the growth and maintenance of nerve cells.

BDNF activates the mTOR signaling pathway, which promotes synaptogenesis — the rapid formation of new synaptic connections between neurons. Research suggests that depression and chronic stress can weaken or destroy these connections, particularly in brain regions associated with mood regulation, such as the prefrontal cortex and hippocampus. Ketamine appears to help rebuild them, sometimes within hours of a single dose.

This ability to promote neuroplasticity — the brain's capacity to reorganize and form new neural pathways — is widely considered the key to ketamine's rapid therapeutic effects.

Dissociative Properties

Ketamine is classified as a dissociative anesthetic. At therapeutic doses used in psychiatric treatment, patients may experience mild to moderate dissociation, which can include feelings of detachment from one's body or surroundings, altered perception of time, and a dreamlike mental state. These effects are temporary, typically lasting 30 to 90 minutes, and are managed through careful monitoring during treatment sessions.

Some researchers and clinicians believe that the dissociative experience itself may contribute to therapeutic outcomes, potentially allowing patients to gain new psychological perspectives on entrenched thought patterns. Others view it primarily as a side effect rather than a therapeutic mechanism. This remains an active area of investigation.

Medical and Psychiatric Uses

Anesthesia and Emergency Medicine

Ketamine's original application remains important today. It is widely used in emergency departments for procedural sedation, in battlefield and field medicine where monitoring equipment may be limited, in pediatric anesthesia where its safety profile is particularly valued, and in developing nations where its room-temperature stability and wide safety margin make it an indispensable tool.

Treatment-Resistant Depression

The psychiatric applications of ketamine gained momentum in 2000 when researchers at Yale University published a landmark study showing that a single low-dose intravenous infusion produced rapid antidepressant effects in patients with major depression. Since then, hundreds of clinical studies have confirmed these findings.

Treatment-resistant depression, defined as depression that has not responded to at least two adequate trials of conventional antidepressants, affects roughly 30% of people diagnosed with major depressive disorder. For these individuals, ketamine offers hope where previous treatments have failed. Many patients report noticeable improvement within hours to days rather than weeks.

Anxiety Disorders

Research has increasingly demonstrated that ketamine may be effective for anxiety disorders, including generalized anxiety disorder, social anxiety disorder, and specific phobias. The glutamate-mediated mechanisms that underlie ketamine's antidepressant effects also appear relevant to anxiety-related brain circuits, particularly the prefrontal cortex and amygdala.

Chronic Pain

Ketamine's role in pain management predates its psychiatric applications. It is used for complex regional pain syndrome (CRPS), neuropathic pain, fibromyalgia, and other chronic pain conditions that resist conventional analgesics. Pain-focused protocols often involve higher doses and longer infusion durations compared to psychiatric protocols.

Other Conditions

Clinical research is exploring ketamine's potential for post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar depression, suicidal ideation, and substance use disorders. The evidence base varies by condition, but early results across multiple psychiatric diagnoses have been encouraging.

Administration Methods

Ketamine therapy is available through several delivery methods, each with distinct characteristics regarding onset time, duration, bioavailability, and clinical setting requirements.

Intravenous (IV) Infusion

IV infusion is the most extensively studied method for psychiatric applications. The standard protocol involves a dose of 0.5 mg/kg administered over 40 minutes. IV delivery provides 100% bioavailability, precise dose control, and the ability to adjust in real time. A typical initial treatment course consists of six infusions over two to three weeks, followed by individually tailored maintenance sessions.

Intranasal (Nasal Spray)

The S-enantiomer of ketamine, known as esketamine and marketed as Spravato, received FDA approval in 2019 for treatment-resistant depression. It is administered as a nasal spray in certified healthcare settings under direct medical supervision, with a required two-hour observation period after each dose.

Oral and Sublingual

Oral and sublingual formulations are increasingly prescribed through telehealth programs for at-home use. These compounded formulations offer lower bioavailability (approximately 20-30% for oral, 25-35% for sublingual) but greater accessibility and lower per-session cost. They are typically used under the guidance of a prescribing provider with virtual monitoring.

Intramuscular (IM) Injection

Intramuscular injection offers a middle ground between IV infusion and oral formulations. It provides higher bioavailability than oral routes (approximately 93%) with a faster onset than sublingual administration, though without the precise real-time control that IV delivery allows.

The Two Forms of Ketamine

The ketamine molecule exists in two mirror-image forms, known as enantiomers:

• S-ketamine (esketamine) — This form has approximately two to four times higher affinity for NMDA receptors compared to R-ketamine. The FDA-approved nasal spray Spravato contains only this enantiomer.
• R-ketamine (arketamine) — This form is currently under investigation and has shown promising antidepressant properties in preclinical and early clinical studies, potentially with fewer dissociative side effects.

Most ketamine used in clinical practice is racemic ketamine, meaning it contains equal parts of both S- and R-ketamine. The clinical significance of using one form versus the other remains an active and important area of research.

Safety and Side Effects

Ketamine therapy conducted under appropriate medical supervision has demonstrated an acceptable safety profile across numerous clinical studies. However, it is not without risks and side effects.

Common Side Effects

The most frequently reported effects during and shortly after treatment include dissociation or altered perception, dizziness, nausea (experienced by approximately 30-40% of patients), transient increases in blood pressure and heart rate, blurred vision, and fatigue. These effects are typically mild to moderate and resolve within one to two hours after treatment.

Who Should Not Receive Ketamine

Contraindications include uncontrolled high blood pressure, active psychotic disorders such as schizophrenia, current substance use disorder involving ketamine or PCP, untreated hyperthyroidism, significantly elevated intracranial pressure, and pregnancy. Each patient should undergo thorough medical screening before beginning treatment.

Long-Term Considerations

Long-term safety data for therapeutic ketamine use at clinical doses is still being accumulated. Concerns about potential bladder toxicity, which is well-documented in chronic heavy recreational users, have not materialized at standard therapeutic doses and frequencies in clinical studies. Cognitive effects and dependence risk at clinical doses also appear low but continue to be monitored in ongoing research.

Legal Status

In the United States, ketamine is a Schedule III controlled substance under the Controlled Substances Act. It is legal for medical use when prescribed and administered by licensed healthcare providers. Off-label prescribing of ketamine for psychiatric conditions is a lawful and widely accepted medical practice, though it is not FDA-approved specifically for this purpose (with the exception of Spravato for treatment-resistant depression and major depressive disorder with suicidal ideation).

Regulations surrounding ketamine vary by state, particularly regarding telehealth prescribing, compounding pharmacy practices, and at-home administration protocols. Patients should verify that their provider operates within applicable legal and regulatory frameworks.

What to Know Before Considering Ketamine Therapy

If you are exploring ketamine therapy, there are several important factors to consider:

• Medical evaluation is essential — A thorough assessment by a qualified provider should precede any treatment to identify contraindications and determine whether ketamine is appropriate for your condition.
• Set realistic expectations — While ketamine can produce rapid improvement, it is not universally effective. Response rates in clinical studies for depression range from approximately 50% to 70%.
• Understand the commitment — Ketamine therapy is not a one-time treatment. Most protocols involve an initial series of sessions followed by periodic maintenance treatments.
• Cost varies significantly — Treatment costs range from roughly $100 per month for compounded at-home formulations to $400-$800 per session for in-clinic IV infusions. Insurance coverage varies widely.
• Ongoing research — The field of ketamine therapy is evolving rapidly. New formulations, delivery methods, and combination approaches continue to emerge from clinical trials.

Important: Ketamine therapy should always be pursued under the care of a qualified healthcare provider. Self-medication with ketamine carries serious risks including adverse cardiovascular events, psychological distress, and potential for misuse.

References

• StatPearls: Ketamine — Comprehensive clinical reference covering ketamine pharmacology, indications, mechanism of action, and adverse effects
• MedlinePlus: Ketamine Injection — National Library of Medicine drug information on ketamine including uses, dosage, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depression including treatment-resistant depression
• WHO Model List of Essential Medicines — World Health Organization's list confirming ketamine's status as an essential medicine
• FDA: Spravato Prescribing Information — Official FDA labeling for esketamine nasal spray including approved indications, dosing, and safety information
• Mayo Clinic: Depression (Major Depressive Disorder) — Overview of depression symptoms, causes, and treatment approaches including emerging therapies